PURPOSE:
Desmoplastic melanoma is a rare subclass of melanoma with unique clinical implications. Recent advances in immunotherapy have been shown to be highly effective in the treatment of this type of melanoma. Currently, patients with positive sentinel node biopsies may be candidates for adjuvant immunotherapy without a completion lymphadenectomy. Staging in melanoma relies heavily on sentinel lymph node biopsies. The rate of positive sentinel nodes in desmoplastic melanoma is lower than other sybtypes yet rates of visceral recurrence are similar and rates of local recurrenc are actually higher. Therefore, staging desmoplastic melanoma and predicting those that may benefit from upfront check point inhibitor therapy is difficult. The purpose of this study is to identify patients that are likely to have recurrence utilizing pathological characteristics, mutation analysis and sentinel lymph node biopsies and clinical/demographic characteristics.
METHODS:
From 1998 to 2017, 109 patients with desmoplastic melanoma underwent treatment in the Yale Melanoma Unit. Of these, 71 patients had sentinel lymph node biopsies. All dermatopathology reports, sentinel lymph node biopsy results, demographics, and clinical outcomes were recorded for all patients. A binomial logistic regression was performed with the coefficients of depth of the initial pathology, age, and the number of positive nodes from the sentinel lymph node biopsy. All statistics were done utilizing SPSS 24.
RESULTS:
Desmoplastic melanoma had a recurrence rate of 25% in our cohort. The average age of diagnosis was 69.6 (±13.3) years. The average depth of the desmoplastic melanoma was 4.1 (±3.8) mm. Only 13% of the patients had a positive sentinel lymph node biopsy; 78% of them had complete lymphadenectomies subsequently. Of the patients that had complete lymphadenectomy after a positive sentinel lymph node biopsy, 83% had a recurrence: 40% were intransit and 60% were distant metastasis. The binomial logistic regression calculated an odds ratio of recurrence for depth of 1.03 (p=0.28, CI: 0.82-1.29), for age of 1.07 (p=0.03, CI: 1.01-1.14) and for a positive lymph node of 20.76 (p=0.01, CI: 2.52-171.34).
CONCLUSION:
In this study, we study pathological characteristics, sentinel lymph node biopsies, and overall clinical outcomes. We found that histological characteristics were not a factor in recurrence. A positive sentinel lymph node biopsy and age were statistically significant factors in determining recurrence. Therefore, it is probably beneficial to provide patients with positive sentinel lymph node biopsies upfront check point inhibitor therapy as a preventative treatment for recurrence. However, we believe that there continues to be a subset of patients that have negative sentinel nodes or no sentinel node biopsy that would benefit for adjuvant immunotherapy. We are currently sequencing the desmoplastic tumors from this study to evaluate for mutations that may predict recurrence better than a sentinel node biopsy.
Discrepancies In Opioid Prescription And Utilization Following Breast Reduction
Nick Wingate, MD, Mark Balceniuk, MD, Alap Patel, BA, Jose Guilherme Christiano, MD University of Rochester Medical Center, Rochester, NY, USA PURPOSE: To examine opioid prescribing patterns after reduction mammoplasty and to assess percentage of pills that are actually consumed. Background: Prescription opioids are a major contributor to the opioid epidemic. Data to inform surgeons regarding inpatient pain control protocols are improving, but data describing the appropriate outpatient opioid regimen is lacking.
METHODS:
We evaluated 247 cases of reduction mammoplasty performed from 6/2015 to 2/2018 at a single institution with four surgeons. Postoperative opioid prescriptions, prescribers, and refill data were tabulated. A phone survey was conducted to determine the percentage of opioid pills consumed.
RESULTS:
There was a wide variation in the number of opioid pills prescribed to patients undergoing reduction mammoplasty at a single institution. The mean number (and range) prescribed was 38 (10-60) pills. The mean (and range) of morphine equivalents prescribed was 230.5 (75-675). 78% of patients consumed 25% or less of the pills prescribed. 14% of patients took no narcotics or never filled their prescription. Approximately 15% of patients obtained refills. Average refill prescription was for 35 pills. There is a large variation in prescribing habits among providers for the same procedure. Only one of the 12 prescribing providers prescribed the same number of morphine equivalents routinely. We identified the number of pills that suffice the opioid needs of 80% of patients undergoing reduction mammoplasty to be 20 pills. Compared to the current average 38 pill prescription, this would be a 47% reduction of opioid pills prescribed.
CONCLUSION:
We demonstrate wide variability of discharge opioid prescribing habits within a single institution. In many cases, excess pills are prescribed initially at discharge and again with refill prescriptions. Using our ideal number, plastic surgeons can decrease the number of opioids prescribed for this common procedure. 
